04:35 PM EST, 11/25/2024 (MT Newswires) -- Aptose Biosciences ( APTO ) , a clinical-stage precision oncology company, after trade Monday said it closed a best-efforts public offering of share units that raised US$8 million.

The offering involved the sale of 40-million units priced at US$0.20 each and made up of a share and one half of a five-year warrant to buy a second share for US$0.25.

The company proceeds will be used for working capital and general corporate purposes.

Aptose shares closed down $0.01 to $0.26 on the Toronto Stock Exchange.